Int J Nanomed:王金铃研究组在纳米胶束给药系统研究中取得进展

2017-04-29 佚名 北京中医药大学中药现代研究中心

一直以来,化疗是肿瘤治疗的主要手段,但化疗药物的毒副作用及肿瘤多药耐药性,严重影响疗效。而通过纳米给药系统等制剂学方法,提高化疗药物的肿瘤靶向性、降低毒副作用并逆转肿瘤多药耐药性,是解决这一难题的有效途径,也是当前的研究热点之一。北京中医药大学中药现代研究中心王金铃博士选择抗肿瘤药阿霉素和中药有效成分姜黄素为研究对象,基于多功能、多靶点和协同增效等复合肿瘤治疗理念,将功能性纳米胶束给药系统优势与中

一直以来,化疗是肿瘤治疗的主要手段,但化疗药物的毒副作用及肿瘤多药耐药性,严重影响疗效。而通过纳米给药系统等制剂学方法,提高化疗药物的肿瘤靶向性、降低毒副作用并逆转肿瘤多药耐药性,是解决这一难题的有效途径,也是当前的研究热点之一。

北京中医药大学中药现代研究中心王金铃博士选择抗肿瘤药阿霉素和中药有效成分姜黄素为研究对象,基于多功能、多靶点和协同增效等复合肿瘤治疗理念,将功能性纳米胶束给药系统优势与中药活性成分联合化疗药物增效减毒优势相结合,构建了阿霉素和姜黄素共递送靶向纳米胶束体系。静注给药后,胶束通过肿瘤高渗透性和滞留效应(EPR效应)被动靶向至肿瘤组织,再进一步主动靶向到肿瘤细胞表面的CD44受体,显着提高了药物的肿瘤靶向性;然后,胶束通过胞吞等方式进入肿瘤细胞,同时释放出姜黄素和阿霉素,发挥协同减毒的效果。体内外结果显示,新构建的胶束体系,不仅能逆转肿瘤多药耐药并降低药物毒副作用,也能显着提高药物的肿瘤靶向和治疗效果,为中药成分联合用于肿瘤治疗的研究提供了借鉴,并为靶向给药制剂的研究与开发奠定基础。

原始出处:

Jinling Wang, Wenzhuan Ma, Qiang Guo, Weigang He, et al.The effect of dual-functional hyaluronic acid-vitamin E succinate micelles on targeting delivery of doxorubicin.Int J Nanomedicine. 2016; 11: 5851–5870.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1607446, encodeId=b7a2160e446c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 01 09:37:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192300, encodeId=b3e119230050, content=感谢分享一下1, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon May 01 00:04:51 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192152, encodeId=277019215242, content=继续研究。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Apr 30 11:51:06 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191950, encodeId=27a219195037, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Sun Apr 30 00:04:53 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1607446, encodeId=b7a2160e446c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 01 09:37:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192300, encodeId=b3e119230050, content=感谢分享一下1, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon May 01 00:04:51 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192152, encodeId=277019215242, content=继续研究。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Apr 30 11:51:06 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191950, encodeId=27a219195037, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Sun Apr 30 00:04:53 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-05-01 laymankey

    感谢分享一下1

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1607446, encodeId=b7a2160e446c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 01 09:37:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192300, encodeId=b3e119230050, content=感谢分享一下1, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon May 01 00:04:51 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192152, encodeId=277019215242, content=继续研究。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Apr 30 11:51:06 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191950, encodeId=27a219195037, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Sun Apr 30 00:04:53 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-04-30 doctorJiangchao

    继续研究。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1607446, encodeId=b7a2160e446c7, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon May 01 09:37:00 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192300, encodeId=b3e119230050, content=感谢分享一下1, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20971999626, createdName=laymankey, createdTime=Mon May 01 00:04:51 CST 2017, time=2017-05-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=192152, encodeId=277019215242, content=继续研究。 , beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Sun Apr 30 11:51:06 CST 2017, time=2017-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=191950, encodeId=27a219195037, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ca432042642, createdName=lemon985, createdTime=Sun Apr 30 00:04:53 CST 2017, time=2017-04-30, status=1, ipAttribution=)]
    2017-04-30 lemon985

    学习

    0